Sucampo Pharma (SCMP) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Mizuho Securities Downgrades Sucampo Pharmaceuticals (SCMP) to Neutral
August 4, 2016 6:24 AM EDTMizuho Securities downgraded Sucampo Pharmaceuticals (NASDAQ: SCMP) from Buy to Neutral with a price target of $13.00.
Analyst Irina Koffler commented, "After the recent run up in SCMP we are moving to the sidelines due to our increased caution about clinical risk and... More
Mizuho Securities Reiterates Buy on Sucampo Pharma (SCMP) as Amitiza Royalies Drives 2Q Beat
August 3, 2016 9:12 AM EDTMizuho Securities reiterated a Buy rating and $14.00 price target on Sucampo Pharmaceuticals (NASDAQ: SCMP) following the company's 2Q earnings report. SCMP reported revenues of $52.0M and $0.23 in EPS vs. consensus of $48.6M and $0.22. The beat was driven primarily by higher royalty revenue from Amitiza... More
